Autor: |
Ziccheddu, Bachisio, Giannotta, Claudia, D'Agostino, Mattia, Bertuglia, Giuseppe, Saraci, Elona, Oliva, Stefania, Genuardi, Elisa, Papadimitriou, Marios, Diamond, Benjamin, Corradini, Paolo, Coffey, David, Landgren, Ola, Bolli, Niccolò, Bruno, Benedetto, Boccadoro, Mario, Massaia, Massimo, Maura, Francesco, Larocca, Alessandra |
Předmět: |
|
Zdroj: |
Blood Cancer Journal; 7/19/2024, Vol. 14 Issue 1, p1-12, 12p |
Abstrakt: |
Targeted immunotherapy combinations, including the anti-CD38 monoclonal antibody (MoAb) daratumumab, have shown promising results in patients with relapsed/refractory multiple myeloma (RRMM), leading to a considerable increase in progression-free survival. However, a large fraction of patients inevitably relapse. To understand this, we investigated 32 relapsed MM patients treated with daratumumab, lenalidomide, and dexamethasone (Dara-Rd; NCT03848676). We conducted an integrated analysis using whole-genome sequencing (WGS) and flow cytometry in patients with RRMM. WGS before and after treatment pinpointed genomic drivers associated with early progression, including RPL5 loss, APOBEC mutagenesis, and gain of function structural variants involving MYC and chromothripsis. Flow cytometry on 202 blood samples, collected every 3 months until progression for 31 patients, revealed distinct immune changes significantly impacting clinical outcomes. Progressing patients exhibited significant depletion of CD38-positive NK cells, persistence of T-cell exhaustion, and reduced depletion of regulatory T cells over time. These findings underscore the influence of immune composition and daratumumab-induced immune changes in promoting MM resistance. Integrating genomics and flow cytometry unveiled associations between adverse genomic features and immune patterns. Overall, this study sheds light on the intricate interplay between genomic complexity and the immune microenvironment driving resistance to Dara-Rd in patients with RRMM. [ABSTRACT FROM AUTHOR] |
Databáze: |
Complementary Index |
Externí odkaz: |
|